Начало・Списък с акции・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

2.97 -1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.96

Максимум

2.99

Ключови измерители
By Trading Economics
Приходи	-9.4M -118M
Продажби	-29M 6.5M
EPS	-0.22
Марж на печалбата	-1,815.575
Служители	600
EBITDA	-13M -102M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+149.32% upside

Дивиденти
By Acuity
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-334M 1.5B
Предишно отваряне	3.97
Предишно затваряне	2.97

Настроения в новините

By Acuity

50%

163 / 340 Класиране в Healthcare

Recursion Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.07.2026 г., 23:11 ч. UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

23.07.2026 г., 19:16 ч. UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

22.07.2026 г., 23:36 ч. UTC

Recursion Pharmaceuticals Inc. shares are near unchanged in after-market hours. The stock remains below its 20-day moving average amid rising crude oil prices.

21.07.2026 г., 23:51 ч. UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

20.07.2026 г., 19:46 ч. UTC

Correlated Moves

Recursion Pharmaceuticals is declining, continuing a trend from previous sessions, amid broader declines in the ARK Genomic Revolution ETF and Russell 2000 Index.

Сравнение с други в отрасъла

Ценова промяна

Recursion Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

149.32% нагоре

12-месечна прогноза

Среден 7.38 USD 149.32%

Висок 10 USD

Нисък 5.5 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Recursion Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Recursion Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

163 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.